Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
32.17
+2.10 (6.98%)
At close: May 12, 2025, 4:00 PM
32.05
-0.12 (-0.37%)
After-hours: May 12, 2025, 4:09 PM EDT
Company Description
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis.
The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases.
Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Kymera Therapeutics, Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Aug 21, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 188 |
| CEO | Nello Mainolfi |
Contact Details
Address: 500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 United States | |
| Phone | 857 285 5300 |
| Website | kymeratx.com |
Stock Details
| Ticker Symbol | KYMR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001815442 |
| CUSIP Number | 501575104 |
| ISIN Number | US5015751044 |
| Employer ID | 81-2992166 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Nello Mainolfi M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Bruce L. Booth DPHIL, Ph.D. | Co-Founder and Independent Chairman |
| Bruce N. Jacobs CFA | Chief Financial Officer |
| Dr. Jeremy G. Chadwick Ph.D. | Chief Operating Officer |
| Ellen V. Chiniara Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Dr. Jared A. Gollob M.D. | Chief Medical Officer |
| Justine E. Koenigsberg | Vice President of Investor Relations |
| Karen Weisbach | Head of People and Culture |
| Dr. Juliet Williams B.A Ph.D. | Head of Research |
| Noah Goodman M.B.A. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 12, 2025 | SCHEDULE 13G/A | Filing |
| May 9, 2025 | 10-Q | Quarterly Report |
| May 9, 2025 | 8-K | Current Report |
| Apr 30, 2025 | SCHEDULE 13G/A | Filing |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 29, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |